Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.08)
# 2,891
Out of 4,937 analysts
122
Total ratings
43.08%
Success rate
-6.67%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: In-Line | $5 → $7 | $6.39 | +9.55% | 9 | Aug 8, 2025 | |
| HNGE Hinge Health | Maintains: Outperform | $50 → $60 | $55.72 | +7.68% | 1 | Aug 6, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $300 | $267.67 | +12.08% | 6 | Jul 25, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $7 → $8 | $6.78 | +17.99% | 4 | Jul 9, 2025 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $28 | $20.30 | +37.93% | 4 | Jul 9, 2025 | |
| NVST Envista Holdings | Maintains: Outperform | $19 → $23 | $20.22 | +13.78% | 4 | Jul 9, 2025 | |
| MCK McKesson | Maintains: Outperform | $760 → $800 | $672.77 | +18.91% | 6 | Jul 9, 2025 | |
| IQV IQVIA Holdings | Maintains: Outperform | $170 → $180 | $180.09 | -0.05% | 6 | Jul 9, 2025 | |
| HCAT Health Catalyst | Maintains: In-Line | $5 → $4 | $2.70 | +48.42% | 7 | Jul 9, 2025 | |
| AGL agilon health | Maintains: In-Line | $5 → $3 | $0.86 | +247.50% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $70 | $61.83 | +13.21% | 8 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $180 | $157.66 | +14.17% | 8 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $200 | $134.82 | +48.35% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $175 → $180 | $178.36 | +0.92% | 3 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $64.88 | +0.18% | 6 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $9 → $12 | $11.86 | +1.18% | 13 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $20 | $12.53 | +59.68% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $34.40 | +4.65% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $5.78 | +354.15% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $3.43 | +337.32% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $1.92 | +472.92% | 2 | Jan 4, 2022 |
Fortrea Holdings
Aug 8, 2025
Maintains: In-Line
Price Target: $5 → $7
Current: $6.39
Upside: +9.55%
Hinge Health
Aug 6, 2025
Maintains: Outperform
Price Target: $50 → $60
Current: $55.72
Upside: +7.68%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $285 → $300
Current: $267.67
Upside: +12.08%
Teladoc Health
Jul 9, 2025
Maintains: In-Line
Price Target: $7 → $8
Current: $6.78
Upside: +17.99%
Privia Health Group
Jul 9, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $20.30
Upside: +37.93%
Envista Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $20.22
Upside: +13.78%
McKesson
Jul 9, 2025
Maintains: Outperform
Price Target: $760 → $800
Current: $672.77
Upside: +18.91%
IQVIA Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $170 → $180
Current: $180.09
Upside: -0.05%
Health Catalyst
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $4
Current: $2.70
Upside: +48.42%
agilon health
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $0.86
Upside: +247.50%
Jul 9, 2025
Upgrades: Outperform
Price Target: $50 → $70
Current: $61.83
Upside: +13.21%
Jun 12, 2025
Maintains: Outperform
Price Target: $175 → $180
Current: $157.66
Upside: +14.17%
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $134.82
Upside: +48.35%
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $178.36
Upside: +0.92%
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $64.88
Upside: +0.18%
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.86
Upside: +1.18%
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $12.53
Upside: +59.68%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $34.40
Upside: +4.65%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $5.78
Upside: +354.15%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $3.43
Upside: +337.32%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $1.92
Upside: +472.92%